Syngene Reports Q2 FY27 Financial Results with Strong Sequential Performance
Syngene International Ltd 路 Press Release 路 28 Oct 2026, 2:10 am
Syngene Reports Q2 FY27 Financial Results with Strong Sequential Performance Syngene International posted Q2 FY27 revenue from operations of Rs 833 Cr, up 13% QoQ but down 9% YoY due to lower Zoetis revenues and forex hedge losses. Operating EBITDA rose to Rs 147 Cr with margins expanding 600 bps QoQ to 18%, while PAT reached Rs 32 Cr versus a loss of Rs 9 Cr in Q1 FY27. Key operational milestones included signing the first manufacturing agreement for the US Bayview biologics facility and securing additional contracts. CFO Deepak Jain resigned for personal reasons.
Original exchange filing (PDF)
More announcements from Syngene International Ltd
- Intimation of Schedule of Meetings with Analyst/Institutional Investor(s) 路 16 Nov 2026
- Intimation of Schedule of Meeting with Analyst/Institutional Investor(s) 路 13 Nov 2026
- Intimation of Earnings Conference call transcript for Q2 FY2027 路 02 Nov 2026
- Intimation of audio recording for Q2 FY27 post-earnings call 路 29 Oct 2026
- Investor Presentation 路 28 Oct 2026
- Change in Management 路 28 Oct 2026
- Results- Financial Results for September 30, 2026. 路 28 Oct 2026
- Outcome of Board Meeting 路 28 Oct 2026
